Figure 2.

Experimental design for evaluating the efficacy of AAV vectors (serotypes 1, 2 and 8) carrying neuropeptide Y (NPY) and its receptor Y2 in two different transgene orders (NPY/Y2 or Y2/NPY); empty viral cassettes were used as a control. Wistar male rats were injected bilaterally with the viral vectors, followed by subcutaneous kainate injection to induce seizures. Key measurements included latency to the first motor seizure, time spent in motor seizure and latency to status epilepticus. Results from these measurements were used to assess the seizure-suppressant efficacy of the AAV vectors compared to an empty cassette control vector.